Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (GB:0QAH)
LSE:0QAH
Holding GB:0QAH?
Track your performance easily
0QAH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$99.15 - $152.06
Previous Close$115.5
Volume3.49K
Average Volume (3M)10.09K
Market Cap
$290.82B
Enterprise Value$317.32B
Total Cash (Recent Filing)$11.35B
Total Debt (Recent Filing)$37.79B
Price to Earnings (P/E)21.4
Beta0.31
Next Earnings
Oct 31, 2024EPS Estimate
$1.74Last Dividend Ex-Date
Sep 16, 2024Dividend Yield2.64%
Share Statistics
EPS (TTM)5.39
Shares Outstanding2,534,809,312
10 Day Avg. Volume9,119
30 Day Avg. Volume10,091
Standard Deviation0.06
R-Squared0.07
Alpha0.00974
Financial Highlights & Ratios
Price to Book (P/B)1.85
Price to Sales (P/S)4.66
Price to Cash Flow (P/CF)12.90
P/FCF Ratio15.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.08
Enterprise Value/Gross Profit7.21
Enterprise Value/Ebitda16.31
Forecast
1Y Price Target
$140.64Price Target Upside21.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Merck & Company News
Bulls Say, Bears Say
Bulls Say
EarningsMRK's 2Q24 total revenue of $16.1B beats by ~$200M, mainly driven by continued strong performance from Keytruda and Gardasil.
Market ExpansionKeytruda growth is unlikely to slow down anytime given the Keytruda indication expansion in both adjuvant and metastatic settings, continued market penetration globally.
Product PerformanceKeytruda is still looking strong and Winrevair off to what appears to be a solid launch act as a backstop for MRK's shares.
Bears Say
CompetitionCompetitor Summit Therapeutics presented detailed data from their HARMONi-2 Phase 3 trial in PD-L1 positive NSCLC showing a statistically significant median PFS benefit compared to MRK's Keytruda.
Operational IssuesIssues involving the broader vaccine market in China, which continue to evolve, and specific operational issues with its partner Zhifei contributed to weaker than expected 2Q sales and prompted a tempering of the 2H24 growth outlook for the product.
Sales EstimatesThe market appears to be immediately anchoring towards the bear case scenario, essentially complete loss of revenue contribution from Gardasil in China.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.16% Insiders
22.27% Mutual Funds
35.54% Other Institutional Investors
42.02% Public Companies and
Individual Investors
0QAH FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest share price was $99.15 and its highest was $152.06 in the past 12 months.
What is Merck & Company’s market cap?
Currently, no data Available
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Oct 31, 2024 which is in 35 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Jul 30, 2024. The company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.168 by $0.112.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.77 which represents an annual dividend yield of 2.64%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is $1.74.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,534,809,300 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.28 in its last earnings report, beating expectations of $2.168. Following the earnings report the stock price went down -9.127%.
Which hedge fund is a major shareholder of Merck & Company?
Among the largest hedge funds holding Merck & Company’s share is Fisher Asset Management LLC. It holds Merck & Company’s shares valued at 2B.
---
Merck & Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$140.64 (21.77% Upside)
$140.64 (21.77% Upside)
Blogger Sentiment
Bullish
GB:0QAH Sentiment 91%
Sector Average 71%
Sector Average 71%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.27%
12-Months-Change
Fundamentals
Return on Equity
33.39%
Trailing 12-Months
Asset Growth
7.81%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
0QAH Company Deck
---
0QAH Earnings Call
Q2 2024
0:00 / 0:00
---
0QAH Sales Breakdown
45.91% Oncology
22.09% Vaccines
5.64% Hospital Acute Care
5.60% Diabetes
20.75% Other
---
0QAH Stock 12 Month Forecast
Average Price Target
$140.64
▲(21.77% Upside)
Technical Analysis
Merck & Company
―
Pfizer
―
Bristol-Myers Squibb
―
Johnson & Johnson
―
GlaxoSmithKline
―
Best Analysts Covering 0QAH
1 Year
1 Year Success Rate
30/40 ratings generated profit
1 Year Average Return
+14.02%
reiterated a buy rating 16 days ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +14.02% per trade.
---